Marksans Pharma Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 21, 2026, 12:34 pm

Market Cap	8,084 Cr.
Current Price	178
Intrinsic Value	₹199.94
High / Low	271/156
Stock P/E	22.4
Book Value	59.3
Dividend Yield	0.45 %
ROCE	20.0 %
ROE	16.8 %
Face Value	1.00
PEG Ratio	1.95

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Marksans Pharma Ltd

Competitors

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	122 Cr.	97.0	137/84.3	25.3	49.6	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.05 Cr.	1.60	4.02/1.60		0.33	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	3,635 Cr.	334	479/208	76.0	24.3	0.21 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	30.4 Cr.	41.0	79.8/37.2		10.6	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	92.6 Cr.	63.2	63.2/17.0	371	6.93	0.00 %	13.5 %	11.0 %	10.0
Industry Average	20,022.34 Cr	1,100.57		56.98	201.33	0.37%	16.29%	15.20%	6.10

All Competitor Stocks of Marksans Pharma Ltd

Quarterly Result

Metric	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	453	480	486	500	531	586	560	591	642	682	708	620	720
Expenses	372	403	376	398	417	453	450	462	495	543	582	520	576
Operating Profit	80	77	110	102	114	133	110	128	147	139	127	100	144
OPM %	18%	16%	23%	20%	21%	23%	20%	22%	23%	20%	18%	16%	20%
Other Income	14	18	11	10	19	5	17	15	-0	28	15	6	22
Interest	3	2	2	2	2	3	5	3	3	3	3	6	6
Depreciation	14	13	14	14	18	22	21	20	20	21	23	23	27
Profit before tax	78	79	104	97	114	113	100	120	125	143	116	77	133
Tax %	23%	21%	21%	27%	26%	26%	23%	26%	22%	27%	22%	24%	26%
Net Profit	60	62	83	70	84	83	78	89	98	105	91	58	99
EPS in Rs	1.51	1.57	1.81	1.52	1.84	1.84	1.73	1.96	2.13	2.31	2.00	1.29	2.17

Last Updated: December 30, 2025, 1:06 am

Below is a detailed analysis of the quarterly data for Marksans Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Sales, as of Sep 2025, the value is 720.00 Cr.. The value appears strong and on an upward trend. It has increased from 620.00 Cr. (Jun 2025) to 720.00 Cr., marking an increase of 100.00 Cr..
For Expenses, as of Sep 2025, the value is 576.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 520.00 Cr. (Jun 2025) to 576.00 Cr., marking an increase of 56.00 Cr..
For Operating Profit, as of Sep 2025, the value is 144.00 Cr.. The value appears strong and on an upward trend. It has increased from 100.00 Cr. (Jun 2025) to 144.00 Cr., marking an increase of 44.00 Cr..
For OPM %, as of Sep 2025, the value is 20.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Jun 2025) to 20.00%, marking an increase of 4.00%.
For Other Income, as of Sep 2025, the value is 22.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Jun 2025) to 22.00 Cr., marking an increase of 16.00 Cr..
For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
For Depreciation, as of Sep 2025, the value is 27.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 23.00 Cr. (Jun 2025) to 27.00 Cr., marking an increase of 4.00 Cr..
For Profit before tax, as of Sep 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 77.00 Cr. (Jun 2025) to 133.00 Cr., marking an increase of 56.00 Cr..
For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 26.00%, marking an increase of 2.00%.
For Net Profit, as of Sep 2025, the value is 99.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Jun 2025) to 99.00 Cr., marking an increase of 41.00 Cr..
For EPS in Rs, as of Sep 2025, the value is 2.17. The value appears strong and on an upward trend. It has increased from 1.29 (Jun 2025) to 2.17, marking an increase of 0.88.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 5:00 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	630	797	893	767	913	1,000	1,134	1,376	1,491	1,852	2,177	2,623	2,731
Expenses	512	612	757	722	834	868	942	1,037	1,232	1,513	1,719	2,094	2,220
Operating Profit	118	185	136	45	78	132	192	340	259	340	459	529	510
OPM %	19%	23%	15%	6%	9%	13%	17%	25%	17%	18%	21%	20%	19%
Other Income	4	3	9	7	8	5	0	7	42	59	50	70	70
Interest	19	16	10	7	10	10	9	8	8	9	11	12	18
Depreciation	16	16	28	30	27	23	27	36	45	52	74	83	93
Profit before tax	86	156	107	15	50	104	157	302	248	338	424	504	469
Tax %	15%	28%	23%	24%	28%	23%	23%	21%	25%	21%	26%	24%
Net Profit	74	112	83	11	36	80	121	239	187	265	315	383	353
EPS in Rs	1.87	2.67	1.92	0.22	0.80	1.87	2.95	5.76	4.51	5.88	6.92	8.40	7.77
Dividend Payout %	5%	4%	21%	23%	6%	3%	3%	4%	6%	9%	9%	10%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	51.35%	-25.89%	-86.75%	227.27%	122.22%	51.25%	97.52%	-21.76%	41.71%	18.87%	21.59%
Change in YoY Net Profit Growth (%)	0.00%	-77.24%	-60.85%	314.02%	-105.05%	-70.97%	46.27%	-119.28%	63.47%	-22.84%	2.72%

Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	13%
5 Years:	18%
3 Years:	21%
TTM:	17%

Compounded Profit Growth
10 Years:	13%
5 Years:	26%
3 Years:	27%
TTM:	5%

Stock Price CAGR
10 Years:	8%
5 Years:	30%
3 Years:	48%
1 Year:	-34%

Return on Equity
10 Years:	17%
5 Years:	19%
3 Years:	17%
Last Year:	17%

Last Updated: Unknown

Balance Sheet

Last Updated: December 4, 2025, 1:37 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	39	41	41	41	41	41	41	41	41	45	45	45	45
Reserves	90	326	401	392	430	502	595	846	1,161	1,700	2,020	2,422	2,643
Borrowings	173	101	100	110	118	100	30	34	111	123	244	322	332
Other Liabilities	188	207	180	209	142	160	236	307	323	322	372	451	422
Total Liabilities	490	676	722	752	731	802	902	1,228	1,636	2,190	2,681	3,240	3,442
Fixed Assets	146	166	270	267	279	270	303	309	428	486	776	982	1,054
CWIP	0	0	0	0	0	0	0	12	3	10	9	27	7
Investments	0	0	0	0	0	0	0	0	0	1	27	1	1
Other Assets	344	510	452	484	451	533	599	907	1,205	1,694	1,869	2,230	2,381
Total Assets	490	676	722	752	731	802	902	1,228	1,636	2,190	2,681	3,240	3,442

Below is a detailed analysis of the balance sheet data for Marksans Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
For Reserves, as of Sep 2025, the value is 2,643.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,422.00 Cr. (Mar 2025) to 2,643.00 Cr., marking an increase of 221.00 Cr..
For Borrowings, as of Sep 2025, the value is 332.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 322.00 Cr. (Mar 2025) to 332.00 Cr., marking an increase of 10.00 Cr..
For Other Liabilities, as of Sep 2025, the value is 422.00 Cr.. The value appears to be improving (decreasing). It has decreased from 451.00 Cr. (Mar 2025) to 422.00 Cr., marking a decrease of 29.00 Cr..
For Total Liabilities, as of Sep 2025, the value is 3,442.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..
For Fixed Assets, as of Sep 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 982.00 Cr. (Mar 2025) to 1,054.00 Cr., marking an increase of 72.00 Cr..
For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 20.00 Cr..
For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
For Other Assets, as of Sep 2025, the value is 2,381.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,230.00 Cr. (Mar 2025) to 2,381.00 Cr., marking an increase of 151.00 Cr..
For Total Assets, as of Sep 2025, the value is 3,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..

Notably, the Reserves (2,643.00 Cr.) exceed the Borrowings (332.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity +	65	155	31	14	50	27	233	179	99	237	230	207
Cash from Investing Activity +	-4	-33	-123	-21	-39	-13	-60	-45	-84	-259	-141	-49
Cash from Financing Activity +	-29	17	-58	-3	3	-21	-114	-15	80	198	-69	-65
Net Cash Flow	31	138	-150	-10	15	-7	60	118	94	176	21	93

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-55.00	84.00	36.00	-65.00	-40.00	32.00	162.00	306.00	148.00	217.00	215.00	207.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	98	84	89	118	71	64	78	72	97	82	76	75
Inventory Days	102	107	120	151	152	215	155	248	216	192	217	270
Days Payable	83	88	85	129	54	78	71	103	102	91	94	98
Cash Conversion Cycle	118	103	124	140	169	202	163	217	211	183	199	247
Working Capital Days	-13	17	59	77	70	97	87	104	121	122	129	142
ROCE %	37%	44%	23%	4%	10%	18%	25%	38%	23%	22%	21%	20%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	43.85%	43.85%	43.85%	43.85%	43.85%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%	43.87%
FIIs	15.11%	14.90%	15.07%	15.55%	15.57%	18.59%	21.31%	21.95%	22.19%	19.89%	16.92%	8.13%
DIIs	1.46%	3.65%	4.02%	4.76%	5.17%	3.75%	4.10%	4.30%	4.55%	5.50%	5.28%	5.91%
Public	39.57%	37.60%	37.06%	35.81%	35.40%	33.77%	30.70%	29.88%	29.37%	30.74%	33.93%	42.08%
No. of Shareholders	1,98,382	1,88,447	2,07,937	2,37,377	2,54,699	2,35,500	2,48,845	2,59,813	2,57,273	2,56,221	2,65,788	2,55,153

Shareholding Pattern Chart

No. of Shareholders

Marksans Pharma Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Bandhan Small Cap Fund	3,335,509	0.28	54.65	N/A	N/A	N/A
UTI Small Cap Fund	3,156,214	1.14	51.71	2,999,136	2026-02-22 13:00:29	5.24%
Kotak Special Opportunities Fund	2,627,836	3.02	43.06	N/A	N/A	N/A
UTI Aggressive Hybrid Fund	2,248,715	0.55	36.85	2,159,816	2026-02-22 13:00:29	4.12%
UTI Large & Mid Cap Fund	2,113,502	0.62	34.63	2,019,995	2026-02-22 13:00:29	4.63%
KotaK MNC Fund	2,000,000	1.67	32.77	N/A	N/A	N/A
UTI Healthcare Fund	950,851	1.48	15.58	879,497	2026-02-22 10:01:48	8.11%
UTI Retirement Fund	742,011	0.26	12.16	701,714	2026-02-22 13:00:29	5.74%
Kotak Healthcare Fund	500,000	1.82	8.19	N/A	N/A	N/A
JM Small Cap Fund	384,008	1	6.29	N/A	N/A	N/A

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	1.00	1.00	1.00	1.00	1.00
Basic EPS (Rs.)	8.40	6.92	6.41	4.51	5.76
Diluted EPS (Rs.)	8.40	6.92	6.41	4.51	5.76
Cash EPS (Rs.)	10.28	8.59	7.00	5.66	6.71
Book Value[Excl.RevalReserv]/Share (Rs.)	54.44	46.03	38.95	29.88	22.12
Book Value[Incl.RevalReserv]/Share (Rs.)	54.44	46.03	38.95	29.88	22.12
Revenue From Operations / Share (Rs.)	57.88	48.05	40.87	36.42	33.62
PBDIT / Share (Rs.)	13.22	11.23	8.80	7.35	8.46
PBIT / Share (Rs.)	11.38	9.59	7.65	6.25	7.58
PBT / Share (Rs.)	11.12	9.35	7.45	6.05	7.38
Net Profit / Share (Rs.)	8.44	6.95	5.85	4.56	5.83
NP After MI And SOA / Share (Rs.)	8.40	6.92	5.88	4.56	5.83
PBDIT Margin (%)	22.83	23.37	21.52	20.17	25.16
PBIT Margin (%)	19.65	19.96	18.72	17.16	22.53
PBT Margin (%)	19.21	19.45	18.23	16.60	21.95
Net Profit Margin (%)	14.58	14.46	14.32	12.53	17.33
NP After MI And SOA Margin (%)	14.51	14.40	14.37	12.53	17.33
Return on Networth / Equity (%)	15.42	15.19	15.25	15.53	26.90
Return on Capital Employeed (%)	18.66	18.97	18.75	19.93	33.35
Return On Assets (%)	11.74	11.70	12.15	11.39	19.42
Total Debt / Equity (X)	0.01	0.01	0.02	0.03	0.02
Asset Turnover Ratio (%)	0.88	0.89	0.96	1.04	0.73
Current Ratio (X)	4.62	4.78	4.91	3.37	3.02
Quick Ratio (X)	2.85	3.19	3.49	2.18	1.67
Inventory Turnover Ratio (X)	3.58	1.21	1.35	1.30	1.74
Dividend Payout Ratio (NP) (%)	7.14	7.22	3.81	5.47	1.71
Dividend Payout Ratio (CP) (%)	5.86	5.84	3.19	4.41	1.49
Earning Retention Ratio (%)	92.86	92.78	96.19	94.53	98.29
Cash Earning Retention Ratio (%)	94.14	94.16	96.81	95.59	98.51
Interest Coverage Ratio (X)	51.37	45.43	43.67	35.61	43.36
Interest Coverage Ratio (Post Tax) (X)	33.81	29.11	30.07	23.12	30.87
Enterprise Value (Cr.)	9417.36	6244.01	2540.86	1577.14	1869.83
EV / Net Operating Revenue (X)	3.59	2.87	1.37	1.06	1.36
EV / EBITDA (X)	15.72	12.27	6.37	5.24	5.40
MarketCap / Net Operating Revenue (X)	3.84	3.15	1.72	1.25	1.49
Retention Ratios (%)	92.85	92.77	96.18	94.52	98.28
Price / BV (X)	4.08	3.33	1.83	1.55	2.31
Price / Net Operating Revenue (X)	3.84	3.15	1.72	1.25	1.49
EarningsYield	0.03	0.04	0.08	0.10	0.11

After reviewing the key financial ratios for Marksans Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
For Basic EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
For Diluted EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
For Cash EPS (Rs.), as of Mar 25, the value is 10.28. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 10.28, marking an increase of 1.69.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 57.88. It has increased from 48.05 (Mar 24) to 57.88, marking an increase of 9.83.
For PBDIT / Share (Rs.), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 11.23 (Mar 24) to 13.22, marking an increase of 1.99.
For PBIT / Share (Rs.), as of Mar 25, the value is 11.38. This value is within the healthy range. It has increased from 9.59 (Mar 24) to 11.38, marking an increase of 1.79.
For PBT / Share (Rs.), as of Mar 25, the value is 11.12. This value is within the healthy range. It has increased from 9.35 (Mar 24) to 11.12, marking an increase of 1.77.
For Net Profit / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has increased from 6.95 (Mar 24) to 8.44, marking an increase of 1.49.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
For PBDIT Margin (%), as of Mar 25, the value is 22.83. This value is within the healthy range. It has decreased from 23.37 (Mar 24) to 22.83, marking a decrease of 0.54.
For PBIT Margin (%), as of Mar 25, the value is 19.65. This value is within the healthy range. It has decreased from 19.96 (Mar 24) to 19.65, marking a decrease of 0.31.
For PBT Margin (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has decreased from 19.45 (Mar 24) to 19.21, marking a decrease of 0.24.
For Net Profit Margin (%), as of Mar 25, the value is 14.58. This value exceeds the healthy maximum of 10. It has increased from 14.46 (Mar 24) to 14.58, marking an increase of 0.12.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 14.40 (Mar 24) to 14.51, marking an increase of 0.11.
For Return on Networth / Equity (%), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 15.19 (Mar 24) to 15.42, marking an increase of 0.23.
For Return on Capital Employeed (%), as of Mar 25, the value is 18.66. This value is within the healthy range. It has decreased from 18.97 (Mar 24) to 18.66, marking a decrease of 0.31.
For Return On Assets (%), as of Mar 25, the value is 11.74. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 11.74, marking an increase of 0.04.
For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has decreased from 0.89 (Mar 24) to 0.88, marking a decrease of 0.01.
For Current Ratio (X), as of Mar 25, the value is 4.62. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.62, marking a decrease of 0.16.
For Quick Ratio (X), as of Mar 25, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 3.19 (Mar 24) to 2.85, marking a decrease of 0.34.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 1.21 (Mar 24) to 3.58, marking an increase of 2.37.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.14. This value is below the healthy minimum of 20. It has decreased from 7.22 (Mar 24) to 7.14, marking a decrease of 0.08.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 20. It has increased from 5.84 (Mar 24) to 5.86, marking an increase of 0.02.
For Earning Retention Ratio (%), as of Mar 25, the value is 92.86. This value exceeds the healthy maximum of 70. It has increased from 92.78 (Mar 24) to 92.86, marking an increase of 0.08.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.14. This value exceeds the healthy maximum of 70. It has decreased from 94.16 (Mar 24) to 94.14, marking a decrease of 0.02.
For Interest Coverage Ratio (X), as of Mar 25, the value is 51.37. This value is within the healthy range. It has increased from 45.43 (Mar 24) to 51.37, marking an increase of 5.94.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 33.81. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 33.81, marking an increase of 4.70.
For Enterprise Value (Cr.), as of Mar 25, the value is 9,417.36. It has increased from 6,244.01 (Mar 24) to 9,417.36, marking an increase of 3,173.35.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has increased from 2.87 (Mar 24) to 3.59, marking an increase of 0.72.
For EV / EBITDA (X), as of Mar 25, the value is 15.72. This value exceeds the healthy maximum of 15. It has increased from 12.27 (Mar 24) to 15.72, marking an increase of 3.45.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
For Retention Ratios (%), as of Mar 25, the value is 92.85. This value exceeds the healthy maximum of 70. It has increased from 92.77 (Mar 24) to 92.85, marking an increase of 0.08.
For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.33 (Mar 24) to 4.08, marking an increase of 0.75.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Marksans Pharma Ltd as of February 23, 2026 is: ₹179.33

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 23, 2026, Marksans Pharma Ltd is Undervalued by 0.75% compared to the current share price ₹178.00

Intrinsic Value of Marksans Pharma Ltd as of February 23, 2026 is: ₹199.94

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 23, 2026, Marksans Pharma Ltd is Undervalued by 12.33% compared to the current share price ₹178.00

Last 5 Year EPS CAGR: 11.49%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 23.75%, which is a positive sign. The company has higher reserves (1,040.62 cr) compared to borrowings (146.00 cr), indicating strong financial stability. The company has shown consistent growth in sales (308.54 cr) and profit (227.69 cr) over the years.	The stock has a high average Working Capital Days of 84.33, which may not be favorable. The stock has a high average Cash Conversion Cycle of 173.00, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
1. Net Profit Margin: 14.58%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 18.66% (Industry Average ROCE: 16.29%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.42% (Industry Average ROE: 15.2%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 33.81
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.85
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 22.4 (Industry average Stock P/E: 56.98)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Marksans Pharma Ltd. is a Public Limited Listed company incorporated on 16/04/1992 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24110MH1992PLC066364 and registration number is 066364. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1174.37 Cr. and Equity Capital is Rs. 45.32 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053	Contact not found

Management
Name	Position Held
Mr. Mark Saldanha	Chairman & Managing Director
Mrs. Sandra Saldanha	Whole Time Director
Mr. Varddhman V Jain	Whole Time Director
Dr. Sunny Sharma	Non Executive Director
Mr. Srinivas Mishra	Independent Director
Mr. Digant Mahesh Parikh	Independent Director
Mr. Abhinna Sundar Mohanty	Independent Director
Mrs. Shailaja Vardhan	Independent Director

FAQ

What is the intrinsic value of Marksans Pharma Ltd?

Marksans Pharma Ltd's intrinsic value (as of 23 February 2026) is ₹199.94 which is 12.33% higher the current market price of ₹178.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹8,084 Cr. market cap, FY2025-2026 high/low of ₹271/156, reserves of ₹2,643 Cr, and liabilities of ₹3,442 Cr.

What is the Market Cap of Marksans Pharma Ltd?

The Market Cap of Marksans Pharma Ltd is 8,084 Cr..

What is the current Stock Price of Marksans Pharma Ltd as on 23 February 2026?

The current stock price of Marksans Pharma Ltd as on 23 February 2026 is ₹178.

What is the High / Low of Marksans Pharma Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Marksans Pharma Ltd stocks is ₹271/156.

What is the Stock P/E of Marksans Pharma Ltd?

The Stock P/E of Marksans Pharma Ltd is 22.4.

What is the Book Value of Marksans Pharma Ltd?

The Book Value of Marksans Pharma Ltd is 59.3.

What is the Dividend Yield of Marksans Pharma Ltd?

The Dividend Yield of Marksans Pharma Ltd is 0.45 %.

What is the ROCE of Marksans Pharma Ltd?

The ROCE of Marksans Pharma Ltd is 20.0 %.

What is the ROE of Marksans Pharma Ltd?

The ROE of Marksans Pharma Ltd is 16.8 %.

What is the Face Value of Marksans Pharma Ltd?

The Face Value of Marksans Pharma Ltd is 1.00.